Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

BACKGROUND: To provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL). METHODS: Patients received cemiplimab 3 mg/kg every 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Rischin, Danny, Khushalani, Nikhil I, Schmults, Chrysalyne D, Guminski, Alexander, Chang, Anne Lynn S, Lewis, Karl D, Lim, Annette M, Hernandez-Aya, Leonel, Hughes, Brett G M, Schadendorf, Dirk, Hauschild, Axel, Thai, Alesha A, Stankevich, Elizabeth, Booth, Jocelyn, Yoo, Suk-Young, Li, Siyu, Chen, Zhen, Okoye, Emmanuel, Chen, Chieh-I, Mastey, Vera, Sasane, Medha, Lowy, Israel, Fury, Matthew G, Migden, Michael R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382148/
https://www.ncbi.nlm.nih.gov/pubmed/34413166
http://dx.doi.org/10.1136/jitc-2021-002757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382148/
https://www.ncbi.nlm.nih.gov/pubmed/34413166
http://dx.doi.org/10.1136/jitc-2021-002757

Ejemplares similares